GHK-Cu stands for glycyl-L-histidyl-L-lysine, a tripeptide that binds copper and occurs naturally in human plasma, saliva, and urine. Levels are high in your twenties and decline steadily after that. Most of the research interest comes from what those declining levels appear to correlate with: slower wound healing, reduced collagen production, and degraded skin quality over time.

What makes this compound worth understanding is that it works upstream. It does not drive acute repair the way BPC-157 does. It supports the tissue quality that makes repair possible in the first place. That distinction matters when you are deciding where it fits in a research protocol and what timeline to hold it to.

GHK-Cu is a tripeptide that binds copper in a way that makes it biologically active at the tissue level. When it reaches skin, connective tissue, or a wound site, research suggests it stimulates fibroblasts to produce more collagen and elastin. Fibroblasts are the cells responsible for building the structural proteins that give skin its firmness and tissue its tensile strength.

Beyond collagen synthesis, the compound appears to influence several other repair signals. Studies suggest it promotes angiogenesis, which is the formation of new blood vessels that supply healing tissue. It also appears to reduce inflammatory signaling at wound sites and may support hair follicle function through similar pathways.

The key framing is that GHK-Cu works upstream. It is not triggering an acute repair response the way BPC-157 does at an injury site. It is rebuilding the foundation-level tissue quality that makes repair and regeneration possible. Researchers who expect a fast, felt response will be disappointed. The benefit is structural and shows over weeks, not days.

This is the most important distinction for any researcher evaluating GHK-Cu. The topical research base is substantially stronger than the subcutaneous data. Most of the published wound healing, collagen synthesis, and skin quality studies used topical application, not injection. That matters when you are deciding how to run it.

Topical GHK-Cu has been studied in the context of wound healing, aging skin, hair loss, and scar remodeling. The studies on collagen production in treated skin versus untreated skin are some of the cleaner data points in the peptide research space. The compound penetrates well enough through the skin barrier to reach fibroblasts, especially when the skin is compromised or when penetration is enhanced by delivery vehicles.

Subcutaneous injection data is more limited. The mechanism is plausible: GHK-Cu circulates systemically and could theoretically reach target tissues through the bloodstream. But the published human data on subcutaneous GHK-Cu for skin or connective tissue repair is sparse compared to the topical literature. Researchers running SubQ are working with a less established evidence base.

GHK-Cu is not just a peptide. It is a copper-carrying peptide. When you inject it subcutaneously, you are delivering copper systemically, not just a signaling molecule. Research suggests each milligram of GHK-Cu delivers approximately 150 to 160 micrograms of biologically active copper into systemic circulation.

Copper is an essential mineral, but systemic copper accumulation is not neutral. The body regulates copper carefully. Most people running peptide protocols are not tracking their dietary copper, supplement copper, or baseline serum copper levels before adding a copper peptide subcutaneously. That context matters when evaluating whether the SubQ route is the right choice for a specific researcher.

Topical application changes this picture significantly. When GHK-Cu is applied to the skin surface, the copper that enters the body does so through the skin barrier at a rate that is far lower than systemic injection. The topical research base also reflects this lower systemic exposure, which is one reason the safety profile in topical studies looks clean.

Signs that systemic copper exposure is accumulating can include a distinct metallic or copper taste in the mouth and flushing. If those appear at a 1mg SubQ dose, they indicate systemic copper exposure is occurring. The correct response is to reduce the dose or transition to topical application only.

GHK-Cu does not produce a felt effect. There is no acute response that tells a researcher it is working. This is one of the most common reasons it gets abandoned before it has had time to do anything measurable. Collagen remodeling is a slow biological process. The research timelines reflect that.

For skin quality and texture changes, the data suggests 4 to 8 weeks of consistent use before meaningful differences appear. Collagen production does not accelerate overnight. The structural improvement accumulates gradually, which means the metric is not how you feel after a week but how skin quality and elasticity compare at the 8-week mark.

For hair follicle support, timelines are longer and outcomes are more variable. Research suggests GHK-Cu may support follicles that are thinning rather than reverse established loss where follicles have been inactive long-term. The earlier in the thinning process it is applied, the more likely it is to have a measurable effect.

For connective tissue quality in a broader protocol context, the benefit is foundational rather than acute. Researchers running extended protocols with significant caloric restriction or training load are gradually degrading connective tissue quality. GHK-Cu addresses that degradation at the root rather than responding to injury after it occurs.

Understanding where GHK-Cu sits relative to the other repair compounds clarifies when adding it makes sense and when it is redundant.

BPC-157 drives active repair. It works at injury sites through angiogenesis and growth factor signaling. It produces a more acute and felt response in many researchers. TB-500 works systemically through cell migration and recovery signaling, covering the systemic repair picture that BPC-157 handles locally. These two are complementary, not redundant.

GHK-Cu works differently from both. It is not responding to an injury signal. It is rebuilding the baseline tissue quality that determines how well repair mechanisms function in the first place. Running GHK-Cu alongside BPC-157 and TB-500 is not redundant because it is operating at a different level of the process. If you are only running one repair compound and it is GHK-Cu, understand that it is the foundation layer, not the acute response tool.

In a GLP-1 or GH secretagogue protocol, the typical addition point is after the primary protocol is established and running cleanly. It is not a first add. It is a refinement add for researchers who want to address tissue quality degradation during an extended caloric restriction phase or who have skin, hair, or connective tissue research goals alongside their primary objective.

GHK-Cu in powder form is stable at room temperature before reconstitution. Once reconstituted with bacteriostatic water, store refrigerated at 2 to 8 degrees Celsius and protect from light. Research reference timeframe for use after reconstitution is within 28 days. The compound is sensitive to both light and temperature after reconstitution, and degradation before use is a common reason researchers report inconsistent results.

Timing is not strongly constrained by the available data. Unlike GH secretagogues that require a fasted injection window, GHK-Cu does not appear to have a significant interaction with insulin or food timing. Daily application for topical use at the target area is the standard research approach. Subcutaneous research range is 1 to 2mg per day.

For topical use, a mild copper smell at higher concentrations is normal and not a sign of a problem. Slight redness or skin sensitivity during the first week of use often resolves as the skin adapts. If redness worsens beyond the first week, reduce application frequency rather than stopping entirely.

Microneedling is a meaningful pairing for topical GHK-Cu. The microneedling process creates microchannels in the skin surface that significantly increase absorption of topically applied compounds. The research-informed approach is to apply GHK-Cu after microneedling, not before. Applying before creates a barrier that reduces the needle penetration depth, and the compound is not present at the right moment in the absorption window.

FOR EDUCATIONAL AND RESEARCH PURPOSES ONLY | NOT MEDICAL ADVICE | NOT FOR HUMAN USE GUIDANCE